ArticleBreast cancer research and treatment2014

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Gladys Morrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.